Publicaciones en las que colabora con Iria Vázquez Urio (32)

2024

  1. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2023

  1. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

2022

  1. Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study

    Cancers, Vol. 14, Núm. 23

  2. NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial

    Cancers, Vol. 14, Núm. 20

2020

  1. Assessment of minimal residual disease by next generation sequencing in peripheral blood as a complementary tool for personalized transplant monitoring in myeloid neoplasms

    Journal of Clinical Medicine, Vol. 9, Núm. 12, pp. 1-20

  2. Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design

    PLoS ONE, Vol. 15, Núm. 1

  3. Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma

    Blood, Vol. 135, Núm. 26, pp. 2375-2387

  4. Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project

    Haematologica, Vol. Online ahead of print

  5. Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia

    British Journal of Haematology

  6. Strategy for identification of a potential inherited leukemia predisposition in a 299 patient's cohort with tumor-only sequencing data

    Leukemia Research, Vol. 95

2017

  1. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells

    Biochimica et Biophysica Acta - Gene Regulatory Mechanisms, Vol. 1860, Núm. 6, pp. 721-729

2016

  1. Use of human pharyngeal and palatine tonsils as a reservoir for the analysis of B-cell ontogeny in 10 paired samples

    Clinical Otolaryngology, Vol. 41, Núm. 5, pp. 606-611

2013

  1. Erratum: ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia (Oncogene (2013) 32 (803) DOI: 10.1038/onc.2012.593)

    Oncogene

  2. Functional characterization of the promoter region of the human EVI1 gene in acute myeloid leukemia: RUNX1 and ELK1 directly regulate its transcription

    Oncogene, Vol. 32, Núm. 16, pp. 2069-2078

2012

  1. Overexpression of GATA2 predicts an adverse prognosis for patients with acute myeloid leukemia and it is associated with distinct molecular abnormalities

    Leukemia

2011

  1. Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia

    Haematologica, Vol. 96, Núm. 10, pp. 1448-1456

2010

  1. EVI1 controls proliferation in acute myeloid leukaemia through modulation of miR-1-2

    British Journal of Cancer, Vol. 103, Núm. 8, pp. 1292-1296

2007

  1. Duplication and rearrangement of the MYB oncogene in T-cell acute lymphoblastic leukemia

    CELLULAR ONCOLOGY

  2. Erratum: JAK2-V617F activating mutation in acute myeloid leukemia: Prognostic impact and association with other molecular markers (Leukemia (2007) vol. 21 (2386-2390) 10.1038/sj.leu.2404812)

    Leukemia

  3. JAK2-V617F activating mutation in acute myeloid leukemia: Prognostic impact and association with other molecular markers [15]

    Leukemia